Dr. John H. Halpern
John H. Halpern, M.D. is
Assistant Professor of Psychiatry, Harvard Medical School, Boston, MA,
USA and Associate Director of Alcohol & Drug Abuse Research, Biological
Psychiatry Laboratory, McLean Hospital, Belmont, MA, USA.
He is on the Editorial Board of
John is currently conducting a multi-year study investigating the neurocognitive consequences of ecstasy-abuse, financed by the National Institute on Drug Abuse (NIDA), USA. He is also leading a clinical trial of MDMA-assisted therapy for anxiety, and he has conducted a controlled longitudinal study of neurocognitive- and psychosocial consequences of the legal, spiritual use of peyote (mescaline) by Native Americans.
He authored Treatment of attention-deficit/hyperactivity disorder, and coauthored Now is the Time for AAPL to Demonstrate Leadership by Advocating Positions of Social Importance, Hallucinogens on the Internet: A Vast New Source of Underground Drug Information, Use of Schizophrenia as a Metaphor in U.S. Newspapers, Response of cluster headache to psilocybin and LSD, and Diminished Interleukin-6 Response to Proinflammatory Challenge in Men and Women after Intravenous Cocaine Administration,
John completed peer review work for Experimental & Clinical Psychopharmacology, Cognitive and Behavioral Neurology, Social Science & Medicine, American Journal of Psychiatry, and Archives of General Psychiatry.
John earned his B.A in Biological Sciences with Honors from The University of Chicago, Chicago, IL in 1990 and his M.D. from The State University of New York Health Science Center at Brooklyn, College of Medicine in 1994. Read FDA Approves Study of Ecstasy In Some Terminally Ill Patients. Read his LinkedIn profile.